title: Treatment of T cell lymphoma in dogs.
abstract: Overall, canine lymphoma remains one of the most chemotherapy-responsive cancers in the dog. In addition to the stage and the substage of disease, T cell phenotype is the most consistently important prognostic factor. T cell lymphoma (TCL) in dogs is a heterogeneous disease; dogs with a separate entity of indolent TCL can have a considerably better prognosis than dogs with other forms of lymphoma, and indolent TCL may not always require immediate treatment. In contrast, high-grade TCL is an aggressive disease, and when treated with CHOP-based protocols, dogs with this high-grade TCL have a complete remission rate as low as 40 per cent, relapse earlier and have shorter survival time than dogs with a comparable stage, high-grade B cell lymphoma. This review describes the different disease entities that comprise canine TCL, discusses prognosis for each and treatment options that appear to give the best outcomes.
authors.affiliation: Veterinary Oncology Consultants, Wauchope, New South Wales 2446, Australia.
authors.forename: Antony S
authors.initials: AS
authors.lastname: Moore
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D060787:Neoplasm Grading; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents